Company Overview of F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd. provides in-vitro diagnostics and drugs for cancer and transplantation. The company specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. The company also researches, develops, and produces molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostic...
Founded in 1896
Key Executives for F. Hoffmann-La Roche Ltd
Chief Executive Officer of Roche Group
Compensation as of Fiscal Year 2017.
F. Hoffmann-La Roche Ltd Key Developments
Dermira, Inc. Enters into Licensing Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc
Aug 8 17
Dermira, Inc. announced that it has entered into a licensing agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc., a member of the Roche Group (together Roche). Pursuant to the agreement, Dermira will obtain exclusive, worldwide rights to develop and commercialize lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic dermatitis and all other indications, except Roche will retain certain rights, including exclusive rights to develop and promote lebrikizumab for interstitial lung diseases, such as idiopathic pulmonary fibrosis. Under the terms of the agreement, Dermira will make an initial payment of $80 million to Roche and payments totaling $55 million in 2018. Dermira will also be obligated to make additional payments upon the achievement of certain milestones, comprising $40 million upon the initiation of Dermira’s first Phase 3 clinical study, up to $210 million upon the achievement of regulatory and first commercial sale milestones in certain territories and up to $1.025 billion based on the achievement of certain thresholds for net sales of lebrikizumab for indications other than interstitial lung disease. Upon potential regulatory approval, Dermira will make royalty payments representing percentages of net sales that range from the high single-digits to the high teens. The effectiveness of the agreement is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, as amended (HSR). The transaction is expected to close in the third quarter of 2017 subject to the expiration or termination of the waiting period under HSR.
F. Hoffmann-La Roche Ltd Presents at Pre-Filled Syringes San Diego Summit, Jun-06-2017 04:40 PM
Jun 3 17
F. Hoffmann-La Roche Ltd Presents at Pre-Filled Syringes San Diego Summit, Jun-06-2017 04:40 PM. Venue: HYATT REGENCY MISSION BAY, 1441 Quivira Road, San Diego, California, United States. Speakers: Monica De Bardi, Post Doctoral Researcher.
F. Hoffmann-La Roche Ltd Presents at BIO International Conference 2017, Jun-20-2017 11:15 AM
May 25 17
F. Hoffmann-La Roche Ltd Presents at BIO International Conference 2017, Jun-20-2017 11:15 AM. Venue: San Diego Convention Center, San Diego, CA 2865, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|